BR112022009580A2 - 6-hidroxi canabidivarina para uso, composição para uso como medicamento, e, processo - Google Patents
6-hidroxi canabidivarina para uso, composição para uso como medicamento, e, processoInfo
- Publication number
- BR112022009580A2 BR112022009580A2 BR112022009580A BR112022009580A BR112022009580A2 BR 112022009580 A2 BR112022009580 A2 BR 112022009580A2 BR 112022009580 A BR112022009580 A BR 112022009580A BR 112022009580 A BR112022009580 A BR 112022009580A BR 112022009580 A2 BR112022009580 A2 BR 112022009580A2
- Authority
- BR
- Brazil
- Prior art keywords
- hydroxy
- cbdv
- cannabidivarine
- drug
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
- C07C39/08—Dihydroxy benzenes; Alkylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/001—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain
- C07C37/002—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain by transformation of a functional group, e.g. oxo, carboxyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/68—Purification; separation; Use of additives, e.g. for stabilisation
- C07C37/70—Purification; separation; Use of additives, e.g. for stabilisation by physical treatment
- C07C37/82—Purification; separation; Use of additives, e.g. for stabilisation by physical treatment by solid-liquid treatment; by chemisorption
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1916977.0A GB201916977D0 (en) | 2019-11-21 | 2019-11-21 | Cannibidol-type cannabinoid compound |
| PCT/GB2020/052944 WO2021099783A1 (en) | 2019-11-21 | 2020-11-18 | Cannabidiol-type cannabinoid compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022009580A2 true BR112022009580A2 (pt) | 2022-08-02 |
Family
ID=69137226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022009580A BR112022009580A2 (pt) | 2019-11-21 | 2020-11-18 | 6-hidroxi canabidivarina para uso, composição para uso como medicamento, e, processo |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11590087B2 (https=) |
| EP (1) | EP4061345A1 (https=) |
| JP (1) | JP2023503309A (https=) |
| KR (1) | KR20220103998A (https=) |
| CN (1) | CN114746086A (https=) |
| AU (1) | AU2020388278A1 (https=) |
| BR (1) | BR112022009580A2 (https=) |
| CA (1) | CA3158192A1 (https=) |
| GB (2) | GB201916977D0 (https=) |
| IL (1) | IL293035A (https=) |
| MX (1) | MX2022006046A (https=) |
| PY (1) | PY2076931A (https=) |
| TW (1) | TW202132250A (https=) |
| WO (1) | WO2021099783A1 (https=) |
| ZA (1) | ZA202206386B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| GB201910389D0 (en) | 2019-07-19 | 2019-09-04 | Gw Pharma Ltd | Novel compounds, methods for their manufacture, and uses thereof |
| GB2588576A (en) | 2019-08-27 | 2021-05-05 | Gw Res Ltd | Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease |
| GB201916849D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916846D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916974D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| GB2597321A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB202013765D0 (en) | 2020-09-02 | 2020-10-14 | Gw Res Ltd | Method of preparing cannabinoids |
| GB2602019A (en) | 2020-12-15 | 2022-06-22 | Gw Res Ltd | Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof |
| GB2606334A (en) * | 2021-02-12 | 2022-11-09 | Gw Res Ltd | Use of cannabidivarin in the treatment of seizures associated with canine epilepsy |
| ES3058168T3 (en) * | 2021-05-12 | 2026-03-09 | Jazz Pharmaceuticals Research Uk Ltd | Resorcinol derivative as a pharmaceutically active compound and method of preparation thereof |
| KR20240007921A (ko) * | 2021-05-12 | 2024-01-17 | 지더블유 리서치 리미티드 | 레조르시놀, 이의 제조 방법, 및 이의 용도 |
| GB202206506D0 (en) * | 2022-05-04 | 2022-06-15 | Gw Res Ltd | Crystaline forms of a cannabidiol-like cannabinoid |
| AU2023321655A1 (en) | 2022-08-12 | 2025-02-13 | Jazz Pharmaceuticals Research Uk Limited | Oral solid dosage forms comprising cannabinoids |
| WO2025046488A1 (en) * | 2023-08-30 | 2025-03-06 | BT DE Investments Inc. | Synthetic cannabinoids for use in therapy and for enhancement of wellbeing |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6630507B1 (en) | 1998-04-21 | 2003-10-07 | The United States Of America As Represented By The Department Of Health And Human Services | Cannabinoids as antioxidants and neuroprotectants |
| US10538373B2 (en) | 2002-08-14 | 2020-01-21 | Gw Pharma Limited | Pharmaceutical formulation |
| TWI583374B (zh) * | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| GB2514054A (en) * | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US10441617B2 (en) | 2013-03-15 | 2019-10-15 | Biotech Institute, Llc | Breeding, production, processing and use of medical cannabis |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| GB2531280A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2551985B (en) | 2016-07-01 | 2019-01-30 | Gw Res Ltd | Novel formulation |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| CN109106699A (zh) * | 2017-06-23 | 2019-01-01 | 汉义生物科技（北京）有限公司 | 一种用于治疗癫痫的药物组合物、其制备方法及用途 |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| GB201715919D0 (en) | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
| GB2568471B (en) | 2017-11-15 | 2022-04-13 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2572125B (en) | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
| GB2572126B (en) | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB2572737A (en) | 2018-01-24 | 2019-10-16 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| GB2581517A (en) | 2019-02-22 | 2020-08-26 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2584140A (en) | 2019-05-23 | 2020-11-25 | Gw Res Ltd | Use of cannabidiol in the treatment of epileptic spasms |
| GB2584341B (en) | 2019-05-31 | 2023-03-01 | Gw Res Ltd | Cannabinoid formulations |
| GB2586026A (en) | 2019-07-29 | 2021-02-03 | Gw Res Ltd | Use of cannabidol in the treatment of Dravet syndrome |
| GB201916974D0 (en) * | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
-
2019
- 2019-11-21 GB GBGB1916977.0A patent/GB201916977D0/en not_active Ceased
-
2020
- 2020-11-18 IL IL293035A patent/IL293035A/en unknown
- 2020-11-18 CN CN202080080992.7A patent/CN114746086A/zh active Pending
- 2020-11-18 MX MX2022006046A patent/MX2022006046A/es unknown
- 2020-11-18 GB GB2018139.2A patent/GB2590187B/en not_active Expired - Fee Related
- 2020-11-18 JP JP2022529679A patent/JP2023503309A/ja not_active Ceased
- 2020-11-18 EP EP20815903.8A patent/EP4061345A1/en active Pending
- 2020-11-18 WO PCT/GB2020/052944 patent/WO2021099783A1/en not_active Ceased
- 2020-11-18 BR BR112022009580A patent/BR112022009580A2/pt not_active Application Discontinuation
- 2020-11-18 KR KR1020227020695A patent/KR20220103998A/ko active Pending
- 2020-11-18 CA CA3158192A patent/CA3158192A1/en active Pending
- 2020-11-18 AU AU2020388278A patent/AU2020388278A1/en not_active Abandoned
- 2020-11-19 PY PY202002076931A patent/PY2076931A/es unknown
- 2020-11-20 TW TW109140702A patent/TW202132250A/zh unknown
-
2022
- 2022-05-13 US US17/743,653 patent/US11590087B2/en active Active
- 2022-06-08 ZA ZA2022/06386A patent/ZA202206386B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220103998A (ko) | 2022-07-25 |
| US20220265573A1 (en) | 2022-08-25 |
| US11590087B2 (en) | 2023-02-28 |
| EP4061345A1 (en) | 2022-09-28 |
| GB201916977D0 (en) | 2020-01-08 |
| WO2021099783A1 (en) | 2021-05-27 |
| GB2590187A9 (en) | 2023-05-17 |
| TW202132250A (zh) | 2021-09-01 |
| CN114746086A (zh) | 2022-07-12 |
| CA3158192A1 (en) | 2021-05-27 |
| JP2023503309A (ja) | 2023-01-27 |
| PY2076931A (es) | 2021-07-15 |
| GB2590187A (en) | 2021-06-23 |
| MX2022006046A (es) | 2022-06-24 |
| ZA202206386B (en) | 2023-12-20 |
| GB2590187B (en) | 2024-07-31 |
| IL293035A (en) | 2022-07-01 |
| AU2020388278A1 (en) | 2022-06-16 |
| GB202018139D0 (en) | 2020-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022009580A2 (pt) | 6-hidroxi canabidivarina para uso, composição para uso como medicamento, e, processo | |
| BR112022009539A2 (pt) | 6-hidroxi canabidiol para uso, composição para uso como medicamento, e, processo | |
| PY2076934A (es) | Compuesto cannabinoide de tipo cannabidiol | |
| PY2076926A (es) | Compuesto cannabinoide de tipo cannabidiol | |
| MX2020012041A (es) | Formulacion farmaceutica. | |
| ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
| DOP2013000030A (es) | Compuesto heterociclico y su uso | |
| BR112015023142A8 (pt) | moduladores do p2x7,seu uso, processo de preparação e composição farmacêutico que os compreende | |
| MX2017004761A (es) | Uso de cannabinoides en el tratamiento de enfermedades degenerativas del musculo esqueletico. | |
| BR112014026424A2 (pt) | composto, processo para produzir um composto de di-idrato, composto de benzotiofeno, método para prevenir e/ou tratar uma doença, e, composição farmacêutica | |
| MX2017016376A (es) | Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo. | |
| PY2068174A (es) | Compuesto cannabinoide | |
| MX2018004175A (es) | Derivado oxa espiro, su metodo de preparacion, y sus aplicaciones en medicinas. | |
| MX357392B (es) | Ensayos basados en interrogatorios celulares y uso de los mismos. | |
| PE20200726A1 (es) | Composicion de cannabis | |
| MX2019011629A (es) | Nuevos compuestos que se unen a fxr (nr1h4) y modulan su actividad. | |
| NI201600014A (es) | Compuestos y composiciones como inhibidores de la mek. | |
| AR111793A1 (es) | Fórmula para bebés prematuros que contiene butirato y usos de la misma | |
| BR112018075939A2 (pt) | compostos heterocíclicos como antibacterianos | |
| BR112016011170A8 (pt) | derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica | |
| BR112017021191A2 (pt) | um extrato de indigo naturalis e um processo para preparar o mesmo | |
| UY31651A1 (es) | Nuevos derivados de fluoroglicósidos aromáticos, medicamentos que comprenden estos compuestos y uso de los mismos. | |
| UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
| BR112015002464B8 (pt) | processo para a preparação de carbamat-benzoxazinona, carbamat-benzoxazinona e uso da carbamat-benzoxazinona | |
| MX2020004232A (es) | Composiciones de cannabinoides y sus metodos de uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |